Atreca Locks In $35M Series B Round For Immuno-Oncology Drug Pipeline

0
431

Redwood City, CA based biotech company Atreca has just announced the completion of its $35 million Series B raise. The money will be allocated for its research on the human immune system and how it can better battle against cancer by the right type of antibodies. This could be big for big pharma and biotech stocks that have had Atreca on their radar for some time now.
New investor Wellington Management co-led the round with the anonymous U.S. health care fund that led Atreca’s $56 million Series A back in 2015. The company is now refueled to continue its R&D while ramping up its efforts into development. Management has reported that they plan to choose a clinical candidate from its lead oncology program by the end of 2017.
“This funding enables us to accelerate the acquisition of immune response data central to cancer immunotherapy and to expand and advance our pipeline of novel antibody therapeutics based on those data,” Atreca CEO Tito Serafini, Ph.D., stated.
“We are very pleased with the continued support of our existing investors, as well as the commitment of our new, high-caliber investors,” he added. “With their participation, we continue to build a foundation for long-term growth. This funding enables us to accelerate the acquisition of immune response data central to cancer immunotherapy and to expand and advance our pipeline of novel antibody therapeutics based on those data.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here